Navigation Links
Endologix Comments on Alleged Patent Infringement
Date:10/8/2009

IRVINE, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, acknowledged today that it has become aware that Cook Medical has filed a lawsuit against Endologix in the United States District Court alleging that Endologix infringes two of Cook's U.S. patents.

John McDermott, Endologix President and Chief Executive Officer, said, "We have just become aware of the lawsuit filed by Cook alleging that Endologix infringes two of Cook's patents, one of which was granted in 1991 and the other in 1998. The patent granted in 1991 expires next week. Together with our patent counsel, we are conducting a thorough evaluation and will provide more information as soon as available."

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Additional information can be found on Endologix's Web site at www.endologix.com.

Forward-Looking Statements

Except for historical information contained herein, this news release contains forward-looking statements, specifically related to the alleged claims of infringement. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.

    COMPANY CONTACT:                        INVESTOR CONTACTS:
    Endologix, Inc.                         The Ruth Group
    John McDermott, CEO                     Nick Laudico (646) 536-7030
    (949) 595-7200                          Zack Kubow (646) 536-7020
    www.endologix.com

SOURCE Endologix, Inc.


'/>"/>
SOURCE Endologix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
2. ACRO Comments on NEJM Article on Globalization of Clinical Research
3. Arpida Comments on FDAs Anti-infective Drugs Advisory Committee Outcome
4. SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
5. Arpida Provides Further Comments on the Pivotal Phase III Trials
6. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
7. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
8. GlaxoSmithKline and U.S. Patent and Trademark Office File a Motion to Dismiss Litigation Over Final Regulations
9. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
10. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
11. United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 The ... 233.7 billion by 2025, according to a new ... is anticipated to be predominantly driven by high ... into the large-scale production of new and therapeutically ... influx of drugs at an unprecedented rate into ...
(Date:1/19/2017)... 2017 Conference Call and Webcast to Follow ... it will release results for the fourth quarter of 2016 on ... ... call at 4:30 PM ET on Wednesday, February 15, 2017, during ... financial results and other corporate activities. To participate in the conference ...
(Date:1/19/2017)... Jan. 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ... mitochondrial dysfunction, today announced new additions to its senior ... Chief Medical Officer, and Daniel Geffken as ... Jim Carr , Pharm.D. has been promoted to ... pleased to welcome Doug and Daniel to our management ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... ... A new partnership between Goodwill® and Roadie, Inc. aims to make it easier ... couches to dressers and bicycles. Roadie — the national on-the-way delivery network — will ... through February 28th. , “January is an exciting time when resolutions are made ...
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... combining seaweeds, botanicals and 100 percent pure essential oils, announced the company had a ... Head, SC. , The annual ECRM event gives companies that work in the nutritional, ...
(Date:1/20/2017)... , ... January 20, 2017 , ... Bionic Sports Nutrition ... walks of life, announced it had a successful January ECRM Trade Show in Hilton ... the United States, which allows it to provide its products to all clients at ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an Australian-based ... recently attended the January ECRM Trade Show in Hilton Head, SC, benefiting from ... large range of supplements that keep the body functioning at its peak performance ...
(Date:1/20/2017)... , ... January 20, 2017 , ... Michael and Betsy ... Farber Cancer Institute. For Betsy, the clinical trial has been life-saving as she ... not worsened. , Betsy Brauser was diagnosed with ovarian cancer in 2009. She ...
Breaking Medicine News(10 mins):